Aequus Pharmaceuticals Inc. (AQSZF)

Market Cap	478.54K
Revenue (ttm)	406.05K
Net Income (ttm)	-1.51M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,300
Average Volume	45,398
Open	0.0040
Previous Close	0.0040
Day's Range	0.0040 - 0.0040
52-Week Range	0.0030 - 0.0225
Beta	-0.35
RSI	44.58
Earnings Date	May 1, 2025

About Aequus Pharmaceuticals

Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Country: Canada
• Stock Exchange: OTCMKTS
• Ticker Symbol: AQSZF

Financial Performance

In 2024, Aequus Pharmaceuticals's revenue was 584,237, an increase of 129.21% compared to the previous year's 254,896. Losses were -2.18 million, -26.55% less than in 2023.

Financial numbers in CAD